# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and lowers the price target from $4.5...
UnitedHealthcare's new policy covers implant-free glaucoma surgeries like OMNI, supporting treatment for mild to moderate o...
Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) from Hold to Hold.
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $3.6...
Lake Street analyst Frank Takkinen upgrades Sight Sciences (NASDAQ:SGHT) from Hold to Buy and raises the price target from $...